
    
      This is a Phase I/Phase II open-label single arm trial of dovitinib in combination with
      anastrozole 1 mg daily, exemestane 25 mg daily, or letrozole 2.5 mg daily. Study subjects
      will receive the aromatase inhibitor on which they had previously derived clinical benefit.
    
  